Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking strategy to diabetes management. These innovative drugs operate by mimicking the physiological actions of GLP-1, a hormone produced by the gut in response to meals. By activating GLP-1 receptors in the pancreas, these compounds enhance insulin secretion and inhibit glucag

The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight decrease – they exhibit intriguing differences in